Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AWAWU E IGBINADOLOR

Allopathic & Osteopathic Physicians Internal Medicine Adolescent Medicine

NPI
1386658128
CMS profile
334690
Location
MONROE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,376.29

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $774.12 3
Food and Beverage $602.17 5

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ModernaTX, Inc. $1,117.53 5
ViiV Healthcare Company $125.21 1
Horizon Therapeutics plc $116.56 1
AstraZeneca Pharmaceuticals LP $16.99 1

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AWAWU E IGBINADOLOR

NPI 1386658128 · CMS profile ID 334690

Allopathic & Osteopathic Physicians / Internal Medicine / Adolescent Medicine

MONROE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386658128?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AWAWU E IGBINADOLOR, NPI 1386658128, CMS profile ID 334690. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386658128?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). AWAWU E IGBINADOLOR, NPI 1386658128, CMS profile ID 334690. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386658128?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
AWAWU E IGBINADOLOR, NPI 1386658128, CMS profile ID 334690, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1386658128?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $1,376.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ModernaTX, Inc. $50.0008/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056975117 CMS
ModernaTX, Inc. $293.4108/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056975121 CMS
ModernaTX, Inc. $392.4708/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056975125 CMS
ModernaTX, Inc. $206.7208/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056975129 CMS
ModernaTX, Inc. $174.9308/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056975131 CMS
Horizon Therapeutics plc $116.5605/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987023049 CMS
AstraZeneca Pharmaceuticals LP $16.9903/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014635897 CMS
ViiV Healthcare Company $125.2102/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1001088659 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $825.59 19
PY2020 $250.77 11
PY2021 $613.59 23
PY2022 $635.48 38
PY2023 $1,376.29 8
PY2024 $3,264.02 14
PY2025 $15.40 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,807,545.77 332
PY2024 Recipient $24,803.18 2
PY2024 Principal investigator $5,575,092.65 467
PY2023 Recipient $5,441.70 12
PY2023 Principal investigator $4,002,304.15 759
PY2022 Recipient $99,385.00 2
PY2022 Principal investigator $3,185,482.26 500
PY2021 Recipient $421,014.16 3
PY2021 Principal investigator $3,556,229.85 34
PY2020 Recipient $145,488.66 2
PY2019 Principal investigator $9,471.00 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

469 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170391
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 12/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170393
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 12/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170395
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 12/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170421
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 12/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170423
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 12/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170425
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 12/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170427
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 12/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170429
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 12/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170431
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170433
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170435
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170437
Principal investigator 1 AstraZeneca Pharmaceuticals LP $156.82 12/31/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1155802442
Principal investigator 1 Merck Sharp & Dohme LLC $22,862.79 12/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1136419424
Principal investigator 1 Merck Sharp & Dohme LLC $5,185.28 12/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1136419428
Principal investigator 1 ModernaTX, Inc. $3,000.00 12/30/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153635
Principal investigator 1 PFIZER INC. $548.40 12/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130965255
Principal investigator 1 Eli Lilly and Company $94,900.00 12/24/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1137362779
Principal investigator 1 ModernaTX, Inc. $950.00 12/24/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153633
Principal investigator 1 PFIZER INC. $834.90 12/21/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130965261
Principal investigator 1 Alnylam Pharmaceuticals Inc. $18,491.11 12/20/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121163052
Principal investigator 1 Alnylam Pharmaceuticals Inc. $101,496.80 12/20/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121163054
Principal investigator 1 Alnylam Pharmaceuticals Inc. $550.00 12/18/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121163056
Principal investigator 1 ModernaTX, Inc. $614.25 12/18/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153581
Principal investigator 1 ModernaTX, Inc. $756.00 12/13/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153583
Principal investigator 1 ModernaTX, Inc. $170.10 12/13/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153585
Principal investigator 1 ModernaTX, Inc. $500.00 12/11/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153587
Principal investigator 1 ModernaTX, Inc. $2,799.90 12/06/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153589
Principal investigator 1 Merck Sharp & Dohme LLC $12,500.00 12/03/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1136419420
Principal investigator 1 ModernaTX, Inc. $120.00 12/02/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153579
Principal investigator 1 ModernaTX, Inc. $8,167.23 12/02/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153591
Principal investigator 1 ModernaTX, Inc. $300.00 12/02/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147153593
Principal investigator 1 ModernaTX, Inc. $400.00 12/02/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147153595
Principal investigator 1 ModernaTX, Inc. $300.00 12/02/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147153597
Principal investigator 1 ModernaTX, Inc. $65,366.16 12/02/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147153599
Principal investigator 1 ModernaTX, Inc. $2,500.00 12/02/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147153601
Principal investigator 1 ModernaTX, Inc. $3,300.00 12/02/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147153603
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170385
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 11/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170387
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 11/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170389
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170415
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170417
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170419
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 11/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170439
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 11/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170441
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 11/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170443
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 11/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170445
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 11/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170447
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 11/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170449
Principal investigator 1 PFIZER INC. $22,542.30 11/23/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130986538
Principal investigator 1 PFIZER INC. $388.75 11/20/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1130946540
Principal investigator 1 PFIZER INC. $853.20 11/15/2024 Non-covered Recipient Entity
Monroe Biomedical Research
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 1130917930
Principal investigator 1 Eli Lilly and Company $2,000.00 11/13/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137362417
Principal investigator 1 Eli Lilly and Company $13,232.00 11/13/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1137362777
Principal investigator 1 Bausch Health US, LLC $700.00 11/08/2024 Non-covered Recipient Entity
Research Mate Inc
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151682476
Principal investigator 1 Bausch Health US, LLC $7,500.00 11/08/2024 Non-covered Recipient Entity
Research Mate Inc
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151682503
Principal investigator 1 PFIZER INC. $16,061.50 11/07/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130986532
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170379
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 10/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170381
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 10/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170383
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170397
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170399
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 10/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170401
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 10/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170403
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 10/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170405
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 10/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170407
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 10/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170409
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 10/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170411
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170413
Principal investigator 1 Eli Lilly and Company $5,330.78 10/28/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1137362673
Principal investigator 1 PFIZER INC. $150.00 10/24/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130993531
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,500.00 10/23/2024 Non-covered Recipient Entity
Research Mate Inc
LX9211 No dispute reported 06/30/2026 1081189280
Principal investigator 1 ModernaTX, Inc. $500.00 10/23/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153631
Principal investigator 1 Eli Lilly and Company $513.01 10/17/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137362415
Principal investigator 1 ModernaTX, Inc. $225.00 10/09/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153629
Principal investigator 1 PFIZER INC. $2,624.70 10/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130993526
Principal investigator 1 ModernaTX, Inc. $2,200.00 10/01/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147153393
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170231
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 09/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170233
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 09/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170235
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170237
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 09/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170239
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 09/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170241
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 09/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170243
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 09/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170245
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 09/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170247
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 09/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170249
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170375
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170377
Principal investigator 1 ModernaTX, Inc. $494.10 09/27/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153627
Principal investigator 1 Eli Lilly and Company $4,524.76 09/26/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RETATRUTIDE COMPARED TO TIRZEPATIDE IN ADULTS WHO HAVE OBESITY No dispute reported 06/30/2026 1137363341
Principal investigator 1 ModernaTX, Inc. $116,240.96 09/25/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153625
Principal investigator 1 Chiesi USA, Inc. $2,000.00 09/24/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148223346
Principal investigator 1 Chiesi USA, Inc. $2,000.00 09/24/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148223348
Principal investigator 1 Chiesi USA, Inc. $1,500.00 09/24/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148223350
Principal investigator 1 Chiesi USA, Inc. $500.00 09/24/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148223352
Recipient Eli Lilly and Company $616.00 09/23/2024 Covered Recipient Physician A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1137345896
Recipient Eli Lilly and Company $24,187.18 09/23/2024 Covered Recipient Physician A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1137346424
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,480.00 09/20/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163032
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,650.00 09/18/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121163042
Principal investigator 1 Alnylam Pharmaceuticals Inc. $13,500.00 09/18/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121163044
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $95.00 09/18/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081189364
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $95.00 09/18/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081189366
Principal investigator 1 ModernaTX, Inc. $170.10 09/18/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153391
Principal investigator 1 ModernaTX, Inc. $4,335.00 09/18/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153623
Principal investigator 1 Eli Lilly and Company $3,235.51 09/17/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1137362783
Principal investigator 1 Alnylam Pharmaceuticals Inc. $546.00 09/13/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163030
Principal investigator 1 Alnylam Pharmaceuticals Inc. $682.00 09/13/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163038
Principal investigator 1 ModernaTX, Inc. $41,411.62 09/11/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147153389
Principal investigator 1 ModernaTX, Inc. $900.00 09/11/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153621
Principal investigator 1 PFIZER INC. $37,570.50 09/10/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131018368
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,875.00 09/09/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162974
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,460.00 09/09/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162976
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,290.00 09/09/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162978
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,730.00 09/09/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162980
Principal investigator 1 Alnylam Pharmaceuticals Inc. $195.00 09/09/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162982
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,908.00 09/09/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163012
Principal investigator 1 Alnylam Pharmaceuticals Inc. $9,236.00 09/09/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163014
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,144.00 09/09/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163016
Principal investigator 1 Alnylam Pharmaceuticals Inc. $9,604.00 09/09/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163018
Principal investigator 1 Alnylam Pharmaceuticals Inc. $554.00 09/09/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163020
Principal investigator 1 Alnylam Pharmaceuticals Inc. $720.00 09/09/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163022
Principal investigator 1 Alnylam Pharmaceuticals Inc. $505.00 09/09/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163024
Principal investigator 1 Alnylam Pharmaceuticals Inc. $303.00 09/09/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163026
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/09/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163028
Principal investigator 1 Alnylam Pharmaceuticals Inc. $172.00 09/09/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163034
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,230.00 09/09/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163036
Principal investigator 1 Alnylam Pharmaceuticals Inc. $195.00 09/09/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163050
Principal investigator 1 Alnylam Pharmaceuticals Inc. $280.00 09/06/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163004
Principal investigator 1 Alnylam Pharmaceuticals Inc. $273.00 09/06/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163006
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 09/06/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163008
Principal investigator 1 Alnylam Pharmaceuticals Inc. $109.00 09/06/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163010
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $403.00 09/06/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081189330
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $159.00 09/06/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081189332
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,949.00 09/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162990
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,308.00 09/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162992
Principal investigator 1 Alnylam Pharmaceuticals Inc. $706.00 09/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162994
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,309.00 09/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162996
Principal investigator 1 Alnylam Pharmaceuticals Inc. $110.00 09/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162998
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 09/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163000
Principal investigator 1 Alnylam Pharmaceuticals Inc. $288.00 09/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121163002
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $95.00 09/04/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081189326
Principal investigator 1 ModernaTX, Inc. $325,930.44 09/02/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153619
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170223
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 08/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170225
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 08/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170227
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170353
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170355
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170357
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170359
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170361
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 08/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170363
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 08/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170365
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 08/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170367
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 08/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170369
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 08/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170371
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 08/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170373
Principal investigator 1 Mylan Specialty L.P. $11,076.62 08/26/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel?Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) No dispute reported 06/30/2026 1141407739
Principal investigator 1 ModernaTX, Inc. $2,687.58 08/23/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153387
Principal investigator 1 Alnylam Pharmaceuticals Inc. $6.00 08/22/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170229
Principal investigator 1 Alnylam Pharmaceuticals Inc. $84,829.26 08/21/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121163046
Principal investigator 1 Alnylam Pharmaceuticals Inc. $104,929.50 08/21/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121163048
Principal investigator 1 ModernaTX, Inc. $325.00 08/21/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147153385
Principal investigator 1 Alnylam Pharmaceuticals Inc. $167,006.00 08/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162984
Principal investigator 1 Alnylam Pharmaceuticals Inc. $74,790.00 08/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162988
Principal investigator 1 Bausch Health US, LLC $4,190.00 08/02/2024 Non-covered Recipient Entity
Research Mate Inc
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151682364
Principal investigator 1 Bausch Health US, LLC $4,190.00 08/02/2024 Non-covered Recipient Entity
Research Mate Inc
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151682408
Principal investigator 1 Bausch Health US, LLC $4,190.00 08/02/2024 Non-covered Recipient Entity
Research Mate Inc
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151682416
Principal investigator 1 Bausch Health US, LLC $4,190.00 08/02/2024 Non-covered Recipient Entity
Research Mate Inc
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151682438
Principal investigator 1 Bausch Health US, LLC $4,190.00 08/02/2024 Non-covered Recipient Entity
Research Mate Inc
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151682457
Principal investigator 1 ModernaTX, Inc. $45,481.90 08/01/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153617
Principal investigator 1 PFIZER INC. $43,778.15 08/01/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131028943
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170215
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170217
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 07/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170219
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 07/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170221
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170251
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170253
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170255
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170257
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170259
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170261
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170263
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170265
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 07/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170267
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 07/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170269
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 07/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170271
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 07/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170273
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 07/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170349
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 07/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170351
Principal investigator 1 ModernaTX, Inc. $2,500.00 07/24/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147153377
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $605.00 07/17/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081188382
Principal investigator 1 ModernaTX, Inc. $1,301.25 07/17/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153383
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,400.00 07/05/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1121163040
Principal investigator 1 ModernaTX, Inc. $7,500.00 07/05/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147153379
Principal investigator 1 ModernaTX, Inc. $6,885.00 07/05/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147153381
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170179
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170181
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 06/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170183
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 06/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170185
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170187
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170189
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170191
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170193
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170195
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170197
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170199
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170201
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 06/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170203
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 06/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170205
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 06/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170207
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 06/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170209
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 06/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 06/28/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170213
Principal investigator 1 Chiesi USA, Inc. $2,635.00 06/28/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148221016
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $12,500.00 06/26/2024 Non-covered Recipient Entity
Research Mate Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1081188950
Principal investigator 1 ModernaTX, Inc. $2,252.50 06/26/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153375
Principal investigator 1 Bausch Health US, LLC $950.00 06/21/2024 Non-covered Recipient Entity
Research Mate Inc
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151682318
Principal investigator 1 ModernaTX, Inc. $5,992.50 06/12/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153373
Principal investigator 1 CIPLA USA INC. $585.66 06/07/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
Not supplied No dispute reported 06/30/2026 1154160701
Principal investigator 1 CIPLA USA INC. $749.49 06/07/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
Not supplied No dispute reported 06/30/2026 1154160703
Principal investigator 1 CIPLA USA INC. $784.32 06/07/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
Not supplied No dispute reported 06/30/2026 1154160705
Principal investigator 1 CIPLA USA INC. $332.82 06/07/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
Not supplied No dispute reported 06/30/2026 1154160707
Principal investigator 1 CIPLA USA INC. $488.91 06/07/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
Not supplied No dispute reported 06/30/2026 1154160709
Principal investigator 1 CIPLA USA INC. $897.84 06/07/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
Not supplied No dispute reported 06/30/2026 1154161465
Principal investigator 1 CIPLA USA INC. $416.67 06/07/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
Not supplied No dispute reported 06/30/2026 1154161467
Principal investigator 1 CIPLA USA INC. $696.60 06/07/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
Not supplied No dispute reported 06/30/2026 1154161469
Principal investigator 1 ModernaTX, Inc. $100.50 06/04/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153615
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,451.95 06/04/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardiovascular disease No dispute reported 06/30/2026 1089690803
Principal investigator 1 PFIZER INC. $5,547.60 06/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131067103
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170115
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170119
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170121
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170137
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170139
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170141
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170145
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170149
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170151
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170153
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170155
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170157
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170159
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170161
Principal investigator 1 Eli Lilly and Company $2,022.70 05/31/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1137362421
Principal investigator 1 PFIZER INC. $2,430.00 05/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131079249
Principal investigator 1 ModernaTX, Inc. $6,000.00 05/29/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153613
Principal investigator 1 ModernaTX, Inc. $3,700.00 05/27/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153611
Principal investigator 1 PFIZER INC. $19,845.00 05/24/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131079243
Principal investigator 1 PFIZER INC. $84,937.94 05/23/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131079321
Principal investigator 1 Eli Lilly and Company $62,398.42 05/21/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1137362497
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,248.00 05/17/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162938
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,432.00 05/17/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162940
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,965.00 05/17/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162942
Principal investigator 1 Alnylam Pharmaceuticals Inc. $13,850.00 05/17/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162944
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,379.00 05/17/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162946
Principal investigator 1 Alnylam Pharmaceuticals Inc. $21,606.00 05/17/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162948
Principal investigator 1 Alnylam Pharmaceuticals Inc. $27,482.00 05/17/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162950
Principal investigator 1 Alnylam Pharmaceuticals Inc. $341.00 05/17/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162952
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,432.00 05/17/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162954
Principal investigator 1 ModernaTX, Inc. $11,250.00 05/08/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147153367
Principal investigator 1 ModernaTX, Inc. $10,000.00 05/08/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147153369
Principal investigator 1 ModernaTX, Inc. $7,119.21 05/08/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147153371
Principal investigator 1 PFIZER INC. $26,946.00 05/07/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131079310
Principal investigator 1 PFIZER INC. $3,750.00 05/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131079316
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170107
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170109
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170111
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170113
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170123
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170125
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170127
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170129
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170131
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170133
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170163
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170165
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170169
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170171
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170173
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170175
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170177
Principal investigator 1 PFIZER INC. $4,692.00 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131090399
Principal investigator 1 PFIZER INC. $45.54 04/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131090562
Principal investigator 1 Eli Lilly and Company $669,480.71 04/29/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137362499
Principal investigator 1 ModernaTX, Inc. $63,495.00 04/17/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153365
Principal investigator 1 PFIZER INC. $1,279.80 04/16/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130917003
Principal investigator 1 PFIZER INC. $557.65 04/15/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131018545
Principal investigator 1 CIPLA USA INC. $4,250.00 04/11/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
Not supplied No dispute reported 06/30/2026 1154160011
Principal investigator 1 Chiesi USA, Inc. $6,000.00 04/10/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148218431
Principal investigator 1 ModernaTX, Inc. $3,318.75 04/10/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153361
Principal investigator 1 Chiesi USA, Inc. $920.00 04/05/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148217733
Principal investigator 1 PFIZER INC. $20,498.00 04/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131090405
Principal investigator 1 PFIZER INC. $2,442.60 04/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131091711
Principal investigator 1 ModernaTX, Inc. $1,500.00 04/01/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153363
Principal investigator 1 PFIZER INC. $376.74 03/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131095638
Principal investigator 1 PFIZER INC. $52,691.90 03/30/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131097179
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169885
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169887
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169889
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169891
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169913
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169917
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169929
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169931
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169933
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169935
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169937
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169939
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169941
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169943
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169945
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169949
Principal investigator 1 PFIZER INC. $1,050.00 03/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131095645
Principal investigator 1 ModernaTX, Inc. $36,513.23 03/28/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153609
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,292.16 03/27/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma No dispute reported 06/30/2026 1110841468
Principal investigator 1 PFIZER INC. $1,117.84 03/27/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131095679
Principal investigator 1 PFIZER INC. $52,515.90 03/27/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131097185
Principal investigator 1 SANOFI PASTEUR INC. $5,000.00 03/25/2024 Non-covered Recipient Entity
Pharmaseek,llc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128702682
Principal investigator 1 SANOFI PASTEUR INC. $150.00 03/25/2024 Non-covered Recipient Entity
Pharmaseek,llc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128702684
Principal investigator 1 SANOFI PASTEUR INC. $9,350.00 03/25/2024 Non-covered Recipient Entity
Pharmaseek,llc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128702686
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,527.43 03/20/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Relative to Budesonide and Formoterol Fumarate MDI and Symbicort pMDI in Adult and Adolescent Participants with Inadequately Controlled Asthma No dispute reported 06/30/2026 1110845163
Principal investigator 1 Chiesi USA, Inc. $9,636.00 03/20/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) No dispute reported 06/30/2026 1148217273
Principal investigator 1 Chiesi USA, Inc. $1,750.00 03/20/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A 12 week, randomized, double-blind, multicenter, active controlled, 2-arm parallel group study testing the superiority of CHF 1535 pMDI 800/24g total daily dose (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) compared to CHF 718 pMDI 800g total daily dose (extrafine beclomethasone dipropionate) in adults with asthma on medium or high-dose inhaled corticosteroid. No dispute reported 06/30/2026 1148217361
Principal investigator 1 SANOFI PASTEUR INC. $166,688.48 03/20/2024 Non-covered Recipient Entity
Pharmaseek,llc
A Phase I/II, Randomized, Descriptive, Safety and Immunogenicity Study to Assess Pentavalent Meningococcal ABCYW Vaccine Formulations in Adults (18 to 25 Years of Age) and Adolescents (10 to 17 Years of Age). No dispute reported 06/30/2026 1128702688
Principal investigator 1 PFIZER INC. $2,601.00 03/15/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131095650
Principal investigator 1 ModernaTX, Inc. $37,785.63 03/08/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147153357
Principal investigator 1 PFIZER INC. $6,115.00 03/07/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131095620
Principal investigator 1 Eli Lilly and Company $450,818.61 03/05/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137363339
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,953.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162826
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,148.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162828
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162830
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162832
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162874
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162876
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162878
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162880
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162882
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162884
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162886
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162888
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162890
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162892
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162894
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162896
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162898
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162900
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162902
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162904
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162906
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162908
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,148.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162910
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162912
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,148.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162914
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,148.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162916
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162918
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,536.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162920
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,148.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162922
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,148.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162924
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,148.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162926
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,148.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162928
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,148.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162930
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,148.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162932
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,953.00 03/04/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162934
Principal investigator 1 ModernaTX, Inc. $120.00 03/01/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153359
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169951
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 02/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169953
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 02/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170075
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 02/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170077
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 02/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170079
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 02/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 02/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170083
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 02/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170085
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 02/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170087
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170089
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170091
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170095
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170097
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170099
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170101
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170103
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/29/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121170105
Principal investigator 1 PFIZER INC. $1,836.00 02/24/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131097143
Principal investigator 1 PFIZER INC. $127,309.14 02/24/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131097192
Principal investigator 1 PFIZER INC. $7,911.54 02/22/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131094923
Principal investigator 1 ModernaTX, Inc. $3,040.00 02/21/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153349
Principal investigator 1 ModernaTX, Inc. $31,240.00 02/19/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153607
Principal investigator 1 PFIZER INC. $21,181.95 02/13/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131097137
Principal investigator 1 PFIZER INC. $15,700.00 02/10/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131095626
Principal investigator 1 PFIZER INC. $814.05 02/09/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131095614
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 02/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162834
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 02/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162836
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 02/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162842
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 02/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162844
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 02/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162846
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 02/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162848
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 02/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162850
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 02/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162852
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 02/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162854
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 02/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162856
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 02/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162858
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 02/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162860
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 02/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162862
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 02/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162864
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 02/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162866
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 02/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162868
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 02/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162870
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,406.00 02/02/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162872
Principal investigator 1 ModernaTX, Inc. $115,850.38 02/02/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147153343
Principal investigator 1 ModernaTX, Inc. $113,288.87 02/02/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1147153345
Principal investigator 1 ModernaTX, Inc. $9,467.50 02/02/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153347
Principal investigator 1 ModernaTX, Inc. $1,410.00 02/01/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153351
Principal investigator 1 ModernaTX, Inc. $4,000.00 02/01/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153353
Principal investigator 1 ModernaTX, Inc. $945.60 02/01/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153355
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169877
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169879
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169881
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169883
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169893
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169895
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169897
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169899
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169901
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169903
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169905
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169907
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169909
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169911
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169919
Principal investigator 1 Alnylam Pharmaceuticals Inc. $143.00 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169921
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169923
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169925
Principal investigator 1 Alnylam Pharmaceuticals Inc. $15.40 01/31/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121169927
Principal investigator 1 Eli Lilly and Company $98.40 01/31/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1137363155
Principal investigator 1 Eli Lilly and Company $1,778.94 01/31/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1137363919
Principal investigator 1 Eli Lilly and Company $25,954.00 01/29/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1137363921
Principal investigator 1 PFIZER INC. $9,249.65 01/27/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1131108655
Principal investigator 1 Eli Lilly and Company $1,141.06 01/25/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1137362675
Principal investigator 1 Eli Lilly and Company $496.80 01/25/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1137363343
Principal investigator 1 ModernaTX, Inc. $7,500.00 01/24/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153339
Principal investigator 1 ModernaTX, Inc. $450.00 01/24/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147153341
Principal investigator 1 Bausch Health US, LLC $1,050.00 01/22/2024 Non-covered Recipient Entity
Research Mate Inc
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151682127
Principal investigator 1 Bausch Health US, LLC $1,500.00 01/22/2024 Non-covered Recipient Entity
Research Mate Inc
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151682176
Principal investigator 1 Bausch Health US, LLC $2,800.00 01/22/2024 Non-covered Recipient Entity
Research Mate Inc
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151682194
Principal investigator 1 Bausch Health US, LLC $13,750.00 01/22/2024 Non-covered Recipient Entity
Research Mate Inc
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1151682212
Principal investigator 1 Eli Lilly and Company $621,330.11 01/18/2024 Non-covered Recipient Entity
WCG CLINICAL INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-CENTER STUDY OF INTRAVENOUS BIMAGRUMAB, ALONE OR IN ADDITION TO OPEN LABEL SUBCUTANEOUS SEMAGLUTIDE, TO INVESTIGATE THE EFFICACY AND SAFETY IN OVERWEIGHT OR OBESE MEN AND WOMEN No dispute reported 06/30/2026 1137369998
Principal investigator 1 ModernaTX, Inc. $34,040.74 01/16/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147153605
Principal investigator 1 PFIZER INC. $11.28 01/16/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131018551
Principal investigator 1 PFIZER INC. $469.60 01/16/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131018557
Principal investigator 1 AstraZeneca UK Limited $78,723.55 01/10/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1110838022
Principal investigator 1 Eli Lilly and Company $64,058.04 01/09/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1137362785
Principal investigator 1 Eli Lilly and Company $1,894.74 01/09/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137363153
Principal investigator 1 Eli Lilly and Company $4,899.01 01/08/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137362419
Principal investigator 1 Novartis Pharmaceuticals Corporation $867.99 01/08/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH, LLC
A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-Lowering Therapy (VictORION-Mono) No dispute reported 06/30/2026 1089690347
Principal investigator 1 PFIZER INC. $281.52 01/06/2024 Non-covered Recipient Entity
Monroe Biomedical Research
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131108529
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 01/03/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162838
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,057.00 01/03/2024 Non-covered Recipient Entity
Monroe Biomedical Research
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1121162840
Principal investigator 1 Eli Lilly and Company $26,547.34 01/03/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1137362671
Principal investigator 1 Eli Lilly and Company $128,426.64 01/02/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1137362495
Principal investigator 1 Eli Lilly and Company $87,849.00 01/02/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1137362669
Principal investigator 1 Eli Lilly and Company $248,354.18 01/02/2024 Non-covered Recipient Entity
MONROE BIOMEDICAL RESEARCH
A STUDY OF ORFORGLIPRON (LY3502970) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH DIET AND EXERCISE ALONE (ACHIEVE-1) No dispute reported 06/30/2026 1137362781